Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office. U.S.DE PARTMENT OF COMMERCE

Under the P	Paperwork Reduction	n Act of 1995, no persons are required to re	espond to a collection of information	ation unless it displays a valid OMB control number.				
UTILITY			Attorney Docket No.	2689US1P				
PATENT APPLICATION TRANSMITTAL			Firstl nventor	YASUMA, T.				
			Title	Thienopyridine Derivatives				
(Only for r	new nonprovisional	applications under 37 CFR 1.53(b))	Express Mail Label No.	EV 310941854 US				
See MPEP o		ON ELEMENTS ning utility patent application contents.	ADDRESS TO:	Mail Stop Patent Application Commissioner for Patents P.O. Box 1450 Alexandria VA 22313-1450				
2. Applica See 37 3. Specifi (preferr - Descr - Cross - Stater - Referr or a c - Back - BriefS	t an original and a cant claims small of CFR 1.27. ication red arrangement seriptive title of the investment of the control of	[Total Pages 196] It forth below) rention ted Applications d sponsored R & D sting, a table, sting appendix tion ention	Computer Program S. Nucleotide and/or A (if applicable, all ned a. Compute b. Specifica i. CD	D-R in duplicate, large table or gram (Appendix) Amino Acid Sequence Submission cessary) r Readable Form (CRF) ation Sequence Listing on: -ROM or CD-R (2 copies); or				
- Detail - Claim	led Description		ACCOMPAN	IYING APPLICATION PARTS				
- Abstract of the Disclosure 4. Drawing(s) (35 U.S.C. 113) [Total Sheets] 5. Oath or Declaration [Total Sheets] a. Newly executed (original or copy) b. Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional with Box 18 completed) i. DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) name in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b). 6. Application Data Sheet. See 37 CFR 1.76			9. Assignment Papers (cover sheet & document(s)) 10. 37 CFR 3.73(b) Statement Power of (when there is an assignee) 11. English Translation Document (if applicable) 12. Information Disclosure Copies of IDS Statement (IDS)/PTO-1449 Citations 13. Preliminary Amendment 14. Preliminary Amendment 14. Certified Copy of Priority Document(s) (if foreign priority is claimed) 15. Certified Copy of Priority Document(s) (if foreign priority is claimed) 16. Nonpublication Request under 35 U.S.C. 122 (b)(2)(B)(i). Applicantm ust attach form PTO/SB/35 or its equivalent. 17. Other:Cr.editCardPaymentForm					
18. If a CONTI	INUING APPLICA	ATION, check appropriate box, and su	pply the requisite information	on below and in the firsts entence of the				
Prior application For CONTINUAT	nuation information: FION OF DIVISION of a part of the dis	or in an Application Data Sheet under Divisional Continu	37 CFR 1.76: uation-in-part (CIP) ofp Art U the prior application, from wh on or divisional application at	rior application No.::10/204,593				
o.porati	<u></u>		NDENCE ADDRESS	``.				
☑ Custor	mer Number:	23,115	OR	Correspondence address below				
Name	Mark Chao							
Address	Takeda Pharma	aceuticals North America, Inc.						
	475 Half Day Road		State Illinois	Zip Code 60069				
Country	Country Lincolnshire		Illinois 2/p Code 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069 60069					
	USA		Registration No. (Attorn					
Name (Print/Ty Signature	(Pe) Mark Chao	11/1/20	Trogistication for (Filterin	Data La la la				
Cignature	W/L	aind by 27 CER 4 52(b). The information	in required to obtain or retain	a henefit by the nublic which is to see (and by the				

This collection of information is required by 37 CFR 1.53(b). The information is required to obtain or retain a benefit by the public which is belief (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

FEE TRANSMITTAL for FY 2003

Effective 01/01/2003. Patent fees are subject to annual revision.

Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$) 750.00

C mpl te if Known					
Application Number	tba				
Filing Date	tba				
First Named Inventor	YASUMA, T.				
Examiner Name	HUANG, E.				
Art Unit	1625				
Attorney Docket No.	2689 US1P				

METHOD OF PAYMENT (check all that apply)	FEE CALCULATION (continued)					
Check Credit card Money Other None	3. ADDITIONAL FEES					
✓ Deposit Account:	Large Entity Small Entity					
Denocit	Fee Code		Fee Code	Fee (\$)	Fee Description	Eee Beid
Account Number 500799	1051	130	2051		Surcharge - late filing fee or oath	Fee Paid
Deposit Takeda Chamical Ind. Inc.	1052	50	2052		Surcharge - late provisional filing fee or	
Account Name Takeda Chemical Ind. Inc.					cover sheet	
The Commissioner is authorized to: (check all that apply)	1053	130 2.520	1053 1812		Non-English specification For filing a request for ex parte reexamination	
Charge fee(s) indicated below Credit any overpayments	1804	920*	1804	_,	Requesting publication of SIR prior to	
Charge any additional fee(s) during the pendency of this application	1004	920	1004	920	Examiner action	
Charge fee(s) indicated below, except for the filing fee	1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
to the above-identified deposit account.	1251	110	2251	55	Extension for reply within first month	
FEE CALCULATION	1252	410	2252	205	Extension for reply within second month	
1. BASIC FILING FEE	1253	930	2253		Extension for reply within third month	
Large Entity Small Entity Fee Fee Fee Fee Fee Description Fee Paid	1254		2254	725	Extension for reply within fourth month	
Code (\$)		1,970	2255	985	Extension for reply within fifth month	
1001 750 2001 375 Utility filing fee 750.00	1401	320	2401			
1002 330 2002 165 Design filing fee	1401	320	2401		Notice of Appeal Filing a brief in support of an appeal	
1003 520 2003 260 Plant filing fee 1004 750 2004 375 Reissue filing fee	1402	280	2402		Request for oral hearing	
		1,510	1451		Petition to institute a public use proceeding	
	1452	110	2452	•	Petition to revive - unavoidable	
SUBTOTAL (1) (\$) 750.00		1,300	2453		Petition to revive - unintentional	
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE		1,300	2501		Utility issue fee (or reissue)	
Fee from Ext <u>ra Claims below Fee Paid</u>	1502	470	2502		Design issue fee	
Total Claims20** = X =	1503	630	2503		Plant issue fee	
Independent Claims - 3** = X = =	1460	130	1460	130	Petitions to the Commissioner	
Multiple Dependent	1807	50	180	7 50	Processing fee under 37 CFR 1.17(q)	
Large Entity Small Entity	1806	180	1806	3 180	Submission of Information Disclosure Stmt	
Fee Fee Fee Fee <u>Fee Description</u> Code (\$)	8021	40	802	1 40	Recording each patent assignment per property (times number of properties)	
1202 18 2202 9 Claims in excess of 20	1809	750	2809	375	Filing a submission after final rejection	
1201 84 2201 42 Independent claims in excess of 3 1203 280 2203 140 Multiple dependent claim, if not paid	4040	750			(37 CFR 1.129(a))	
1203 280 2203 140 Multiple dependent claim, if not paid 1204 84 2204 42 ** Reissue independent claims	1810	750	2810	J 375	For each additional invention to be examined (37 CFR 1.129(b))	
over original patent	1801	750	2801	375	Request for Continued Examination (RCE)	
1205 18 2205 9 ** Reissue claims in excess of 20 and over original patent	1802	900	1802	900	Request for expedited examination of a design application	
SUBTOTAL (2) (\$)	Other fee (specify)					
SUBTOTAL (2) (\$) **or number previously paid, if greater; For Reissues, see above	*Red	uced by	Basic	Filing F	ee Paid SUBTOTAL (3) (\$)	

SUBMITTED BY					(Complete (if applicable)		
Name (Print/Type)	Mark Char Ph.D.JD	Registration No. (Attorney/Agent)	37,293	Telephone 847-383-3372			
Signature	alle			Date	9/8/03		

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.